TENX

Tenax Therapeutics, Inc.

NasdaqCMUSDEQUITY DELAYED

1.77

▼ 0.01 (0.57%)

MARKET · —

Price

Open

1.76

Prev close

1.78

Day high

1.84

Day low

1.73

Volume

4.15M

Market cap

—

P/E (TTM)

—

52W range

1.31 – 19.40

Trailing performance

Price return · vs SPY

Returnvs SPY

-2.78% -1.4%

-88.05% -91.8%

-85.84% -88.9%

-85.73% -96.8%

YTD

-85.64% -97.9%

-70.74% -90.7%

-93.25% -167.4%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

1.72

+2.99% from price

SMA 20

8.04

-78.23% from price

SMA 50

11.84

-85.22% from price

SMA 100

12.38

-85.70% from price

SMA 200

12.14

-85.58% from price

EMA 12

4.09

-56.75% from price

EMA 26

7.62

-76.77% from price

EMA 50

10.04

-82.37% from price

RSI (14)

19.8

Oversold

MACD (12,26,9)

-3.53

Hist -0.58

ATR (14)

1.29

73.90% of price

Realised vol 30D

656.1%

Annualised

Bollinger upper

20.76

20, 2σ

Bollinger lower

-4.69

20, 2σ

50 / 200 cross

Death

11.84 vs 12.14

Trend bias

Below 200

-85.58%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.84

Less volatile than market

Correlation to SPY

0.09

Largely independent

Realised vol 30D

656.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-92.5%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

1.29

73.90% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 1.77

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

TENX · links out to the publisher

Chardan Downgrades Tenax Therapeutics to Neutral From Buy, Adjusts Price Target to $5 From $27 MT Newswires · 11d ago Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 MT Newswires · 11d ago Tenax Therapeutics’ stock crashes on Phase III trial failure Clinical Trials Arena · 11d ago Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case MarketBeat · 12d ago Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 InvestorsHub · 12d ago Tenax, Sionna Shares Sink After Trial Failures The Wall Street Journal · 12d ago BC-Most Active Stocks Associated Press · 12d ago Why Did TENX Stock Crash 89% Today? Stocktwits · 12d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.